# Viatris Innovation GmbH: Phase 3 study closed enrollment, 470 enrolled (Lupus Erythematosus, Systemic)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Viatris Innovation GmbH |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus |
| NCT ID | NCT05648500 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Lupus Erythematosus, Systemic |
| Intervention types | drug |
| Target enrollment | 470 |
| Site countries | United States, Argentina, Brazil, Bulgaria, Colombia, France, Greece, India, Japan, Mexico, Philippines, Poland |
| Posted | 2022-12-13 |
| Planned start | 2022-12-13 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 470 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05648500). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.